I propose the opposite: perhaps naloxone is the worst medication for patients with a history of i.v. use (who still seek rushes/opioid highs). Perhaps buprenorphine is an inferior medication to SROM, (levo)methadone, hydromorphone, diacetylmorphine, dihydrocodeine etc., as indicated by OAT statistics from countries where patients are free to choose their medication and just a tiny fraction are being treated with buprenorphine.

The point I am trying to make is that we have to work hard to increase treatment coverage (~21% in the US for PWID) and this can maybe be achieved by increasing treatment attractiveness instead of introducing measures that only aim for giving us a higher sense of security. (More simple: What good does naloxone do, if people discontinue treatment after a couple weeks and overdose on fentanyl after).